[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370280-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370280-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mgmtepimutations-and-risk-of-incident-cancer-of-the-colon-glioblastoma-multiforme-and-diffuse-large-b-cell-lymphomas","MGMTepimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas","","Constitutional BRCA1 epimutations involving promoter hypermethylation are linked to elevated risks of triple-negative breast cancer and high-grade serous ovarian cancer. While MGMT epimutations are common in colon cancer, glioblastoma, and B-cell lymphoma, the relationship between constitutional MGMT epimutations and the risk of developing these malignancies remains unclear. A nested case-control design evaluated blood MGMT epimutations from healthy participants for subsequent incident cancers using sequencing and Cox regression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mgmtepimutations-and-risk-of-incident-cancer-of-the-colon-glioblastoma-multiforme-and-diffuse-large-b-cell-lymphomas/370280/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mgmtepimutations-and-risk-of-incident-cancer-of-the-colon-glioblastoma-multiforme-and-diffuse-large-b-cell-lymphomas/370280.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about MGMT epimutations?","Question",{"text":63,"@type":64},"It tests whether constitutional MGMT promoter methylation in normal tissue is associated with the future risk of developing incident colon cancer, glioblastoma multiforme, or diffuse large B-cell lymphomas.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants and cases selected?",{"text":68,"@type":64},"Participants were postmenopausal women from the Women’s Health Initiative who were cancer-free at entry, with matched incident cases for left- and right-sided colon cancer, diffuse large B-cell lymphomas, and glioblastoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about hazard ratios?",{"text":72,"@type":64},"No significant association was observed between MGMT promoter epimutations and incident cancers; sensitivity analyses of promoter subregions and functional SNP rs16906252 also showed no meaningful effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370280,1790881738,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Nikolaienko et al. Clinical Epigenetics (2025) 17:28 [https://doi.org/10.1186/s13148-025-01835-x](https://doi.org/10.1186/s13148-025-01835-x)  \nClinical Epigenetics  \n RESEARCH Open Access  \nMGMTepimutations and risk of incident  \ncancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas  \nOleksii Nikolaienko1,2, Garnet L. Anderson3, RowanT. Chlebowski4, Su Yon Jung5, Holly R. Harris3, Stian Knappskog1,2 and Per E. Lønning2*  \nAbstract  \nBackground Constitutional BRCA1 epimutations (promoter hypermethylation) are associated with an elevated  \nrisk of triple-negative breast cancer and high-grade serous ovarian cancer. While MGMTepimutations are frequent in colon cancer, glioblastoma, and B-cell lymphoma, it remains unknown whether constitutional MGMTepimutations are associated with risk of any of these malignancies.  \nMethods We designed a nested case–control study, assessing potential associations between MGMTepimutations in blood from healthy individuals and subsequent risk of incident cancer. The study cohort was drawn from postmenopausal women, participating in the Women’s Health Initiative (WHI) study, who had not been diagnosed  \nwith either colon cancer, glioblastoma, or B-cell lymphoma prior to study entry. The protocol included n = 400 women developing incident left-sided and n = 400 women developing right-sided colon cancer, n = 400 women developing diffuse large B-cell lymphomas, all matched on a 1:2 basis with cancer-free controls, and n = 195 women developing incident glioblastoma multiforme, matched on a 1:4 basis. All cancers were confirmed in centralized medical record review. Blood samples, collected at entry, were analyzed for MGMT epimutations by massive parallel sequencing. Associations between MGMT methylation and incident cancers were analyzed by Cox proportional hazards regression. Results Analyzing epimutations affecting the key regulatory area of the MGMT promoter, the hazard ratio (HR) was 1.07 (95% CI 0.79–1.45) and 0.80 (0 .59–1. 08) for right-and left-sided colon cancer, respectively, 1.13 (0 .78–1. 64) for glioblastoma, and 1.11 (0 .83–1.48) for diffuse large B-cell lymphomas. Sensitivity analyses limited to subre  \ngions of the MGMT promoter and to individuals with different genotypes of a functional SNP in the MGMT promoter (rs16906252), revealed no significant effect on HR for any of the cancer forms. Neither did we observe any effect of rs16906252 status on HR for any of the cancer forms among individuals methylated or non-methylatedat the MGMT promoter.  \nConclusions Constitutional MGMT promoter methylation in normal tissue is not associated with an increased risk of developing colon cancer, glioblastoma, or B-cell lymphoma.  \nKeywords Cancer risk, MGMT, Epimutation, Constitutional methylation, Colon cancer, Glioblastoma, B-cell lymphoma  \n*Correspondence:  \nPer E. Lønning  \n[per.lonning@helse-bergen. no](per.lonning@helse-bergen. no)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nNikolaienk","cbCainqVgXeOHgfE","https://ap.wps.com/l/cbCainqVgXeOHgfE","pdf",1384875,11,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What question does the study address about MGMT epimutations?\",\"answer\":\"It tests whether constitutional MGMT promoter methylation in normal tissue is associated with the future risk of developing incident colon cancer, glioblastoma multiforme, or diffuse large B-cell lymphomas.\"},{\"question\":\"How were participants and cases selected?\",\"answer\":\"Participants were postmenopausal women from the Women’s Health Initiative who were cancer-free at entry, with matched incident cases for left- and right-sided colon cancer, diffuse large B-cell lymphomas, and glioblastoma.\"},{\"question\":\"What were the main findings about hazard ratios?\",\"answer\":\"No significant association was observed between MGMT promoter epimutations and incident cancers; sensitivity analyses of promoter subregions and functional SNP rs16906252 also showed no meaningful effects.\"}]","MGMTepimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas | PDF",1790187729,28]